Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of January 3, 2025 • 4:30 AM ET

Date/Time Source News Release
05/09/2024 04:10 PM EDT GlobeNewswire Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations
03/26/2024 08:00 AM EDT GlobeNewswire Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
02/20/2024 08:00 AM EST GlobeNewswire Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
02/06/2024 08:00 AM EST Business Wire Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
11/06/2023 08:00 AM EST GlobeNewswire Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
10/23/2023 07:00 AM EDT GlobeNewswire Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
10/19/2023 08:00 AM EDT GlobeNewswire Ayala Pharmaceuticals Announces Closing of Merger with Biosight
08/10/2023 04:30 PM EDT GlobeNewswire Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update
08/01/2023 08:00 AM EDT GlobeNewswire Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
07/27/2023 08:10 AM EDT GlobeNewswire Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Page

Additional News

As of January 3, 2025 • 4:30 AM ET

Date/Time Source News Release
06/27/2024 02:14 PM EDT SeekingAlpha Immunome: AL102 And Other Established Protein Targets Could Drive Value
05/09/2024 04:18 PM EDT SeekingAlpha Ayala Pharmaceuticals files Form 15 to voluntarily deregister and suspend reporting obligations
02/19/2024 06:00 AM EST US Earnings Reports Expected US Company Earnings on Monday, February 19th, 2024
02/19/2024 04:30 AM EST US Earnings Reports Expected earnings - Advaxis Inc.
02/06/2024 08:14 AM EST SeekingAlpha Immunome to buy AL102, a phase 3 asset for treatment of desmoid tumors
11/06/2023 06:00 AM EST US Earnings Reports Expected US Company Earnings on Monday, November 6th, 2023
11/06/2023 04:30 AM EST US Earnings Reports Expected earnings - Advaxis Inc.
10/30/2023 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Monday, October 30th, 2023
10/30/2023 05:30 AM EDT US Earnings Reports Expected earnings - Advaxis Inc.
10/23/2023 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Monday, October 23rd, 2023
Page